Factor X (h): 293T Lysate: sc-116234



The Power to Question

BACKGROUND

Hemostasis following tissue injury involves the deployment of essential plasma procoagulants (Prothrombin and Factors X, IX, V and VIII), which are involved in a blood coagulation cascade that leads to the formation of insoluble Fibrin clots and the promotion of platelet aggregation. Coagulation Factor X (Stuart Prower factor, FX, F10) is a vitamin K-dependent, single chain serine protease that is synthesized in the liver and circulates as an inactive precursor. The mature form of Factor X (Factor X A) is generated by Factor IX A- or Factor VII A-mediated cleavage at the tripeptide sequence, Arg-Lys-Arg, to yield a disulfide linked dimer. Together with the cofactor Factor V A and Ca²⁺ on the surface of platelets or endothelial cells, Factor X A coordinates as part of the prothrombinase complex, which mediates proteolysis of Prothrombin into active Thrombin. Mutations at the Factor X locus resulting in Factor X deficiencies can contribute to hemorrhagic diathesis.

REFERENCES

- Davie, E.W., et al. 1975. Basic mechanisms in blood coagulation. Annu. Rev. Biochem. 44: 799-829.
- Di Scipio, R.G., et al. 1977. A comparison of human Prothrombin, Factor IX (Christmas factor), Factor X (Stuart factor), and Protein S. Biochemistry 16: 698-706.
- 3. Davie, E.W., et al. 1991. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30: 10363-10370.
- 4. Macedo-Ribeiro, S., et al. 1999. Crystal structures of the membrane-binding $\rm C_2$ domain of human coagulation Factor V. Nature 402: 434-439.
- Chambers, R.C., et al. 2000. Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of proteaseactivated receptor-1. J. Biol. Chem. 275: 35584-35591.
- Yang, Y.H., et al. 2006. Antibodies against the activated coagulation Factor X (FXA) in the antiphospholipid syndrome that interfere with the FXA inactivation by Antithrombin. J. Immunol. 177: 8219-8225.
- 7. Todd, T., et al. 2006. Severe Factor X deficiency due to a homozygous mutation (Cys364-Arg) that disrupts a disulphide bond in the catalytic domain. Haemophilia 12: 621-624.
- 8. Ndonwi, M., et al. 2007. Substitution of the Gla domain in Factor X with that of Protein C impairs its interaction with Factor VII A/tissue factor: lack of comparable effect by similar substitution in Factor IX. J. Biol. Chem. 282: 15632-15644.
- 9. Al-Hilali, A., et al. 2007. Analysis of the novel Factor X gene mutation Glu51Lys in two families with Factor X-Riyadh anomaly. Thromb. Haemost. 97: 542-545.

CHROMOSOMAL LOCATION

Genetic locus: F10 (human) mapping to 13q34.

PRODUCT

Factor X (h): 293T Lysate represents a lysate of human Factor X transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

Factor X (h): 293T Lysate is suitable as a Western Blotting positive control for human reactive Factor X antibodies. Recommended use: 10-20 µl per lane.


Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

Factor X (AHX-5050): sc-81739 is recommended as a positive control antibody for Western Blot analysis of enhanced human Factor X expression in Factor X transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG κ BP-HRP: sc-516102 or m-lgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz MarkerTM Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

DATA



Factor X (AHX-5050): sc-81739. Western blot analysis of Factor X expression in non-transfected: sc-117752 (A) and human Factor X transfected: sc-116234 (B) 293T whole cell Ivsates.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com